证券代码：300497 证券简称：富祥药业 公告编号：2026-011 江西富祥药业股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 江西富祥药业股份有限公司（以下简称"公司"）近日收到控股股东、实际控制 人、董事长包建华先生关于其所持有的公司部分股份解除质押的通知，具体情况如下： 一、股东部分股份解除质押的基本情况 2、股东股份累计被质押的情况 截至本公告披露日，包建华先生及其一致行动人所持股份质押情况如下： | | | | 本次解除质 | 本次解除质 | 占其所 | 占公司 | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 持股数量 | 持股 | | | | | 已质押股份 | 占已质 | 未质押股份 | | | 名称 | (股) | 比例 | 押前质押股 | 押后质押股 | 持股份 | 总股本 | 限售和冻结 | 押股份 | 限售和冻结 | 占未质押 | | ...

Group 1: Financial Performance and Product Impact - The price of 6-APA has decreased by approximately 45% to 180 RMB/kg as of January 19, 2026, positively impacting the gross margin of core products like Tazobactam and Sulbactam, which together account for about 40% of the company's revenue in 2024 [2][3] - The new production process for Tazobactam is expected to lower production costs while enhancing product quality, thus improving market competitiveness [3] Group 2: Market Demand and Product Synergy - Piperacillin, a key β-lactam antibiotic, is crucial for combination formulations that address bacterial resistance, with its demand closely tied to downstream formulations [4] - The market demand for Piperacillin is driven by ongoing clinical needs for anti-infection treatments and the increasing application of combination formulations due to rising antibiotic resistance [4] Group 3: Capacity Expansion and Strategic Planning - The company plans to expand VC (Vinyl Carbonate) production capacity from 8,000 tons/year to 10,000 tons/year, with a long-term goal of 20,000 tons/year, driven by the growing demand in the battery market [5] - The expansion is characterized by low investment and quick response to market needs, minimizing overall risk while maximizing economic benefits [5] Group 4: Innovative Protein Development - The "Weiran Protein" product line focuses on high-protein, high-fiber, and low-residue applications, targeting markets such as artificial meat and health foods [6][7] - The company has established competitive advantages in the synthetic biology protein sector, including proprietary strains and advanced technology, positioning itself as a leader in the market [6][7] - Collaborations with academic institutions and the establishment of the "Weiran New Quality Protein Alliance" aim to drive market education and product innovation [7]

证券日报网讯 1月20日，富祥药业在互动平台回答投资者提问时表示，公司产品的销售价格会根据市场 供需、客户需求及原材料成本等多方面因素进行动态调整。不同纯度等级的产品因生产工艺复杂度、质 量控制成本及满足客户特定需求的能力不同，其市场价格存在合理差异。 （编辑 丛可心） ...

证券日报网讯 1月20日，富祥药业在互动平台回答投资者提问时表示，公司正在加快国内外市场布局， 根据各地区各替代场景，深度开发和完善应用，为全球蛋白原料B端客户提供解决方案和服务；同时创 新未冉蛋白新食品新应用，有节奏地孵化和建设C端品牌、营销和供应链，全面经营快消、大健康等业 务。目前，公司孙公司未冉商盟（上海）食品科技有限公司已有多款产品上市销售，如未冉魔方椰肽 水、肽润草本水、肽爽气泡水等产品。 （编辑 丛可心） ...

Core Viewpoint - The company, Fuxiang Pharmaceutical, is actively managing its production plans for lithium battery electrolyte additives based on market demand, inventory levels, and annual production planning [1] Group 1 - The production plan for lithium battery electrolyte additives is dynamically formulated and managed according to market orders and inventory conditions [1] - During the Spring Festival, the company will coordinate arrangements to ensure stable operation of order delivery and production systems [1]

Core Insights - The article emphasizes the rising importance of biomanufacturing as a strategic and innovative sector, which is seen as a new growth point that can help optimize industrial structures and transform economic models [1]. Group 1: Current State and Trends - The "2025 China Synthetic Biomanufacturing Industry Development White Paper" was officially released on August 1, highlighting the current status and trends in biomanufacturing [1]. - The report analyzes the global biomanufacturing industry, including key platform facilities and a comparative study of the US and China in this field [5]. Group 2: Policy Landscape - The white paper discusses major policies affecting biomanufacturing both domestically and internationally for the years 2024-2025 [5]. Group 3: Industry Map and Applications - It provides a comprehensive map of the Chinese biomanufacturing industry and analyzes the industry chain along with key application directions, including biomanufacturing in pharmaceuticals, food, personal care, agriculture, chemicals, materials, and energy [5]. Group 4: Key Enterprises - The report identifies ten leading enterprises in the Chinese biomanufacturing sector, detailing their contributions and roles within the industry [5][6]. Group 5: Company Strategies - It outlines the synthetic biology strategies of 15 listed companies, summarizing their development approaches and corresponding popular products [5][6]. Group 6: Investment and Challenges - The white paper reviews the investment and financing situation in domestic synthetic biology from 2024 to mid-2025 and discusses the challenges faced by the biomanufacturing industry in China, along with proposed countermeasures [5][6].

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of January 19, 2026 [1] Core Insights - 2025 marked a significant year for Chinese innovative drugs going global, with a total transaction amount of $135.655 billion, including $7 billion in upfront payments and 157 deals, setting historical highs. The trend continues into 2026, with notable licensing agreements from companies like Yilian Biotech and Rongchang Biotech, indicating strong global competitiveness for Chinese innovative drugs [2] - Major companies are increasingly investing in the small nucleic acid field, with significant acquisitions and clinical approvals. For instance, China National Pharmaceutical Group acquired Hangzhou Hejiya Biopharmaceutical for 1.2 billion RMB, while international firms like Novartis and GSK are also advancing in this area [3] - The GLP-1 market is expected to grow despite new pricing systems, with ongoing collaborations and new product launches anticipated in 2026. The market for GLP-1 drugs is projected to remain robust due to the large patient population for weight loss and diabetes [4] - The oral autoimmune drug market is gaining attention, with promising results from Takeda's new TYK2 inhibitor for psoriasis. Other domestic companies are also advancing in this space, exploring new targets for oral small molecules [5] - The brain-computer interface sector is poised for industrialization, with companies like Neuralink set to produce devices in 2026. Domestic advancements and regulatory support are enhancing the potential for this technology in medical applications [6] - The ZAP-X radiation therapy device is expected to capture a significant market share in China, with rapid growth projected in non-invasive tumor radiation treatment, driven by increasing clinical recognition and adoption [8] Summary by Sections Industry Trends - The pharmaceutical sector is witnessing a resurgence in interest towards innovative drugs, with a notable increase in the innovative drug index by 8.97% since early January 2026, outperforming the CSI 300 index by 6.77 percentage points [2] Company Recommendations - Recommended companies include: - **Yuekang Pharmaceutical** and **Sunshine Nuohua** in the small nucleic acid space - **Yahong Pharmaceutical** and **Yifang Biotechnology** in the autoimmune sector - **Zhongsheng Pharmaceutical** in the GLP-1 market - **Baiyang Pharmaceutical** for ZAP-X radiation therapy - **Meihao Medical** for brain-computer interface technology [10] Market Opportunities - The non-invasive tumor radiation treatment market is projected to grow from 27.2 billion RMB in 2018 to 59.4 billion RMB by 2024, with a compound annual growth rate of 13.9% [8]

Group 1 - The company, 富祥药业, announced that its fifth board meeting for the sixth session will be held on January 16, 2026, in Jingdezhen City, focusing on the proposal regarding expected daily related transactions for the year 2026 [1] Group 2 - The silver market has seen a significant increase, with prices rising over 80% in the last 50 days, indicating a potential peak in the precious metals bull market, which is historically associated with heightened speculation in silver [1]

证券代码：300497 证券简称：富祥药业 公告编号：2026-007 江西富祥药业股份有限公司 关于调整公司第一期股票期权激励计划相关事项的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 江西富祥药业股份有限公司（以下简称"公司"）于2026年1月16日召开了第五届 董事会第六次会议，审议通过了《关于调整公司第一期股票期权激励计划相关事项的 议案》《关于向公司第一期股票期权激励计划激励对象首次授予股票期权的议案》。 根据《上市公司股权激励管理办法》《江西富祥药业股份有限公司第一期股票期权激 励计划（草案）》的相关规定及公司2025年第三次临时股东会的授权，董事会对公司 第一期股票期权激励计划相关事项进行调整，现将有关调整事项说明如下： 2、2025年11月28日-2025年12月7日，公司对本激励计划首次授予激励对象姓名和 职务在公司内部进行了公示，公司员工可在公示期内通过书面方式或邮件方式向董事 会薪酬与考核委员会反馈意见。截至公示期满，公司董事会薪酬与考核委员会未收到 任何员工对本次公示的内容存有异议。2025年12月8日，公司董事会薪酬与考核委员 ...

江西富祥药业股份有限公司 第一期股票期权激励计划首次授予激励对象名单（首次授予日） 注 2：上述任何一名激励对象通过全部有效的股权激励计划获授的本公司股票均未超过本激励 计划草案公告时公司股本总额的 1%。公司全部有效的激励计划所涉及的标的股票总数累计不超过 本激励计划草案公告时公司股本总额的 10%。激励对象因个人原因自愿放弃获授权益的，由董事会 对授予数量作相应调整。 注 3：预留部分的激励对象由本激励计划经股东会审议通过后 12 个月内确定，经董事会提出、 董事会薪酬与考核委员会发表明确意见、律师事务所发表专业意见并出具法律意见书后，公司在指 定网站按要求及时准确披露当次激励对象相关信息。 二、公司核心骨干（含合并报表范围内子公司）人员名单 | 序号 | 姓名 | 职务 | 序号 | 姓名 | 职务 | | --- | --- | --- | --- | --- | --- | | 1 | 屠亚东 | 核心骨干员工 | 21 | 朱旭杰 | 核心骨干员工 | | 2 | 李英涛 | 核心骨干员工 | 22 | 姚建 | 核心骨干员工 | | 3 | 陶伟锋 | 核心骨干员工 | 23 | 俞琴 | 核心 ...